The prostate cancer section is a comprehensive resource for urology news and expert insights. Read more at Urology Times.

Key Takeaways Rogaratinib and atezolizumab combination therapy shows promising efficacy in urothelial carcinoma, with a 53.8% overall response rate, independent of PD-L1 or FGFR3 status. The ...

Additional data from the phase 3 NIAGARA trial (NCT03732677) bolster the safety and efficacy of perioperative durvalumab (Imfinzi) plus neoadjuvant chemotherapy followed by radical cystectomy and ...

Low-intensity extracorporeal shock wave therapy is a safe treatment for men with erectile dysfunction and might work to improve, or even cure, ED in some patients. But there remain important ...

Key Takeaways Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed ...

Key Takeaways UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of ...

Key Takeaways Anktiva is the first drug to rescue T and NK cells, crucial for cancer cell eradication and memory generation. The "triangle offense" involves NK cells, CD8 killer T cells, and memory T ...

The guideline, which was first published in 2020, outlines recommendations for the diagnosis, evaluation, and follow-up of patients with microhematuria. 2 According to the authors, the aim was to ...

In this interview, Mohit Khera, MD, MBA, MPH, shares insights on the use of testosterone replacement therapy in men with prostate cancer, touching on current evidence and also stressing the importance ...

The AUA released its guidelines in 2018, making a strong recommendation that clinicians should inform patients of the absence of evidence linking testosterone therapy to the development of prostate ...

Key Takeaways The FDA will evaluate talazoparib and enzalutamide for mCRPC patients unselected for HRR gene alterations, expanding beyond HRR-positive cases. TALAPRO-2 trial data showed significant ...

Experts review different treatment delivery options available for the management of non–muscle-invasive bladder cancer (NMIBC), discuss the exciting developments in NMIBC with several delivery systems ...